ESTRO 2024 - Abstract Book

S311

Brachytherapy - Head & neck, skin, eye

ESTRO 2024

with Monte Carlo calculated detector correction factors provide vendor independent traceability. The methodology offers hospitals a feasible way to verify absorbed dose-rate to water depth dose curves and so increase safety of patient treatments and fulfillment of regulatory requirements.

Keywords: Dosimetry, Metrological Traceability

References:

[1] Thomson R M, Furutani K M, Kaulich T W, Mourtada F, Rivard M J, Soares C G, Vanneste F M and Melhus C S 2020 AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221 Med Phys 47 e92-e124 [2] Andreo P, Burns D T, Hohlfeld K, Huq M S, Kanai T, Laitano F, Smyth V and Vynckier S 2000 Absorbed Dose Determination in External Beam Radiotherapy: An International Code of Practice for Dosimetry Based on Absorbed Dose to Water IAEA Technical Report Series no 398 (Vienna: International Atomic Energy Agency)

1960

Proffered Paper

Comparing Swallowing Function in OTSCC after HDRIBT followed by IMRT (HyBIRT) with Surgery.

Kai Ping Ong 1 , MY Musa 1,2,3 , Irfan Mohamad 4 , GK Appalanaido 5,6

1 USM Bertam Medical Centre, Clinical Medicine, Penang, Malaysia. 2 Advanced Medical and Dental Institute, Clinical Medicine, Penang, Malaysia. 3 USM Bertam Medical Centre, otorhinolaryngology, Penang, Malaysia. 4 School of Medical Sciences, USM, otorhinolaryngology, kota Bharu, Malaysia. 5 Advanced Medical and Dental Institute, Medical Imaging, Penang, Malaysia. 6 USM Bertam Medical Centre, Radiation Oncology, Penang, Malaysia

Purpose/Objective:

The clinical outcome and rationale of Hybrid HDRIBT followed by IMRT (HyBIRT) technique for the definitive treatment of oral tongue SCC (OTSCC) was presented as a proffered paper during ESTRO 2023 (1). Current follow up study compares the swallowing which is the most important functional outcome that affects the QOL in OTSCC patient undergoing HyBIRT technique or surgery as the primary modality (2)

Material/Methods:

This cross-sectional study enrolled 32 histologically confirmed OTSCC patients [12 patients in the HyBIRT group (HyBIRT) and 20 patients in the surgery group (SG)] between June 2022 and October 2023. Patients are enrolled only if imaging confirmed radiological CR and remain disease free for at least 6 months after treatment. The median age is 59.7 and 58 years and median follow-up from last treatment is 11.67 and 30 months. TNM7 stage is T1 (5% vs 10%), T2 (15% vs 45%), T3 (20% vs 25%), T4a (60% vs 20%), N0 (15% vs 30%), N1 (15% vs 30%), N2 (70% vs35%), N3 (0% vs 5%) for HyBIRT and SG, respectively. In the SG 25% had wide local resection, 35% hemi glossectomy, 15% subtotal glossectomy and 25% total glossectomy with 30% able to have primary closure, 65% needed Flap reconstruction and 70% had post operative radiotherapy. Swallowing was assessed using three primary metrics: the swallowing capacity scale (SCS), the EAT-10 score and the Penetration-Aspiration Scale (PAS)